Search Results

There are 1403 results for: content related to: Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials

  1. You have free access to this content
    Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk and Christian Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005642.pub3

  2. You have free access to this content
    Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Jesper Brok, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud and Lise Lotte Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005441.pub3

  3. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus

    Intervention Review

    The Cochrane Library

    Alfonso Iorio, Emanuela Marchesini, Tahany Awad and Lise Lotte Gluud

    Published Online : 20 JAN 2010, DOI: 10.1002/14651858.CD004888.pub2

  4. You have free access to this content
    Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

    Alimentary Pharmacology & Therapeutics

    Volume 26, Issue 3, August 2007, Pages: 369–376, R. BRUNO, P. SACCHI, C. SCAGNOLARI, F. TORRIANI, L. MAIOCCHI, S. PATRUNO, F. BELLOMI, G. FILICE and G. ANTONELLI

    Version of Record online : 29 MAY 2007, DOI: 10.1111/j.1365-2036.2007.03392.x

  5. Boceprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 32, Issue 2, February 2012, Pages: 173–190, Olga M. Klibanov, Stephen B. Vickery, Jacqueline L. Olin, Lisa S. Smith and Shannon H. Williams

    Version of Record online : 30 JAN 2012, DOI: 10.1002/PHAR.1046

  6. You have free access to this content
    Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin

    Alimentary Pharmacology & Therapeutics

    Volume 27, Issue 5, March 2008, Pages: 433–440, V. K. RUSTGI, S. ESPOSITO, F. M. HAMZEH and M. L. SHIFFMAN

    Version of Record online : 10 DEC 2007, DOI: 10.1111/j.1365-2036.2007.03587.x

  7. You have free access to this content
    Peginterferon vs. standard interferon in the treatment of chronic hepatitis C

    Alimentary Pharmacology & Therapeutics

    Volume 18, Issue 7, October 2003, Pages: 661–670, A. Zaman, M. B. Fennerty and E. B. Keeffe

    Version of Record online : 19 SEP 2003, DOI: 10.1046/j.1365-2036.2003.01747.x

  8. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy

    Journal of Viral Hepatitis

    Volume 18, Issue 4, April 2011, Pages: e81–e90, S. Mauss, D. Hueppe, C. John, J Goelz, R. Heyne, B. Moeller, R. Link, G. Teuber, A. Herrmann, M. Spelter, S. Wollschlaeger, A. Baumgarten, K.-G. Simon, N. Dikopoulos and T. Witthoeft

    Version of Record online : 16 SEP 2010, DOI: 10.1111/j.1365-2893.2010.01372.x

  9. You have free access to this content
    The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis

    HIV Medicine

    Volume 8, Issue 5, July 2007, Pages: 312–321, AI Kim, A Dorn, R Bouajram and S Saab

    Version of Record online : 7 JUN 2007, DOI: 10.1111/j.1468-1293.2007.00476.x

  10. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients

    Intervention Review

    The Cochrane Library

    Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili and Ran Tur-Kaspa

    Published Online : 12 SEP 2012, DOI: 10.1002/14651858.CD008516.pub2

  11. You have free access to this content
    Nitazoxanide for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Kristiana Nikolova, Christian Gluud, Berit Grevstad and Janus C Jakobsen

    Published Online : 6 APR 2014, DOI: 10.1002/14651858.CD009182.pub2

  12. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C

    Journal of Viral Hepatitis

    Volume 14, Issue 10, October 2007, Pages: 721–729, A. M. Di Bisceglie, R. H. Ghalib, F. M. Hamzeh and V. K. Rustgi

    Version of Record online : 26 APR 2007, DOI: 10.1111/j.1365-2893.2007.00862.x

  13. You have free access to this content
    Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C

    Hepatology

    Volume 46, Issue 3, September 2007, Pages: 640–648, Nicole Forestier, Hendrik W. Reesink, Christine J. Weegink, Lindsay McNair, Tara L. Kieffer, Hui-May Chu, Susan Purdy, Peter L.M. Jansen and Stefan Zeuzem

    Version of Record online : 24 AUG 2007, DOI: 10.1002/hep.21774

  14. You have free access to this content
    Diagnosis, management, and treatment of hepatitis C: An update

    Hepatology

    Volume 49, Issue 4, April 2009, Pages: 1335–1374, Marc G. Ghany, Doris B. Strader, David L. Thomas and Leonard B. Seeff

    Version of Record online : 2 DEC 2008, DOI: 10.1002/hep.22759

  15. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response

    Journal of Viral Hepatitis

    Volume 13, Issue 6, June 2006, Pages: 371–376, C. D. Howell, L. S. Jeffers, W. Cassidy, K. R. Reddy, S. Hu and J. S. Lee

    Version of Record online : 3 APR 2006, DOI: 10.1111/j.1365-2893.2005.00697.x

  16. You have free access to this content
    Results of the IDEAL trial: “Mirror, mirror on the wall … Which's the fairest peg-interferon of them all?”

    Hepatology

    Volume 50, Issue 6, December 2009, Pages: 2034–2037, Julian Schulze zur Wiesch and Ansgar W. Lohse

    Version of Record online : 20 NOV 2009, DOI: 10.1002/hep.23376

  17. You have free access to this content
    Benefits and risks of interferon therapy for hepatitis B

    Hepatology

    Volume 49, Issue S5, May 2009, Pages: S103–S111, Robert Perrillo

    Version of Record online : 27 APR 2009, DOI: 10.1002/hep.22956

  18. You have full text access to this OnlineOpen article
    Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study

    British Journal of Clinical Pharmacology

    Volume 79, Issue 3, March 2015, Pages: 514–522, Xiao Hu, Yue Cui, Joleen White, Ying Zhu, Aaron Deykin, Ivan Nestorov and Serena Hung

    Version of Record online : 20 FEB 2015, DOI: 10.1111/bcp.12521

  19. Peginterferon α-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B

    Journal of Viral Hepatitis

    Volume 10, Issue 4, July 2003, Pages: 298–305, W. G. E. Cooksley, T. Piratvisuth, S.-D. Lee, V. Mahachai, Y.-C. Chao, T. Tanwandee, A. Chutaputti, W. Yu Chang, F. E. Zahm and N. Pluck

    Version of Record online : 23 JUN 2003, DOI: 10.1046/j.1365-2893.2003.00450.x

  20. Peginterferon Alfa-2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy

    Clinical Pharmacology & Therapeutics

    Volume 77, Issue 3, March 2005, Pages: 214–224, Mark Sulkowski, Teresa Wright, Stephen Rossi, Sanjeev Arora, Matthew Lamb, Ka Wang, Jean-Michel Gries and Sreeni Yalamanchili

    Version of Record online : 7 MAR 2005, DOI: 10.1016/j.clpt.2004.09.008